GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2006

CytoGenix’ Gene Silencing ssDNA Technology Patent Allowed in Europe and India

  • CytoGenix received notices of allowances for grant of patent applications covering the technology for expressing ssDNA in vivo from the Indian and European Community Patent Offices. These notices follow the previous notice of allowance for these applications from the Peoples Republic of China.

    Filed in 1999 and 2000, these patents cover the company's single-strand DNA expression system covered by a U.S. patent. It is used in the company's Simplivir™ antiherpes and CY303 anti-inflammation products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »